Abstract
In comparison to other European countries, during the first months of COVID-19 pandemic, Poland reported relatively low number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. To estimate the scale of pandemic in Poland, a serosurvey of antibodies against SARS-CoV-2 was performed after the first wave of COVID-19 in Europe (March – May 2020). Within this study, we collected samples from July 28 to September 24, 2020 and based on the ELISA results, we found that 1.67% (25/1500, 95%CI 1.13 - 2.45) of the Poznan (Poland) metropolitan area’s population had antibodies against SARS-CoV-2 after the first wave of COVID-19. However, the presence of anti-SARS-CoV-2 IgG antibodies was confirmed with immunoblot in 56% (14/25) samples, what finally resulted in decrease of seroprevalence, i.e. 0.93% (14/1500, 95%CI 0.56 - 1.56). The positive anti-SARS-CoV-2 IgG results were associated with age, occupation related to constant contact with people, travelling abroad, non-compliance with epidemiological recommendations and direct contact with the novel coronavirus. Our findings confirm the low SARS-CoV-2 incidence in Poland and imply that the population had little herd immunity heading into the second and third wave of the pandemic, and therefore herd immunity contributed little to prevent the high numbers of SARS-CoV-2 infections and COVID-19 related deaths in Poland during these subsequent waves.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Science Center (Poland), grant UMO-2020/01/0/NZ6/00152.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Bioethics Committee at the Poznan University of Medical Sciences, Poznan, Poland (Resolution No. 470/20 from 17th June 2019).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The manuscript contains all available data, which can be shown according to the Polish and European law.
